NCT02464020View on ClinicalTrials.gov

A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

May 1, 2017

Study Completion Date

December 1, 2018

Conditions
Primary Sclerosing CholangitisInflammatory Bowel Disease
Interventions
DRUG

Vancomycin

Oral vancomycin: 500mg suspended in prefilled syringes for oral use

Trial Locations (1)

55455

University of Minnesota Medical Center, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT02464020 - A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis | Biotech Hunter | Biotech Hunter